查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961160

肌萎縮側索硬化症 (ALS) 治療市場 - 全球產業規模、佔有率、趨勢、機會、預測：按療法、類型、分銷管道、地區和競爭格局分類，2021-2031 年

Amyotrophic Lateral Sclerosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肌萎縮側索硬化症 (ALS) 治療市場預計將從 2025 年的 6.9203 億美元成長到 2031 年的 9.7667 億美元，複合年成長率為 5.91%。

該市場涵蓋多種藥物干預措施和緩解疾病，旨在控制症狀、延緩神經退化並延長患有這種進行性運動神經元疾病的患者的生存期。推動這一成長的關鍵因素包括全球肌萎縮側索硬化症 (ALS) 發病率的上升和人口老化，這兩方面都增加了對有效神經系統護理的需求。此外，對基因研究和開發以及新型生物標記發現的大量投資正在推進臨床開發平臺，為超越暫時性市場波動的長期產業擴張奠定了堅實的基礎。

市場概覽
預測期 2027-2031
市場規模：2025年 6.9203億美元
市場規模：2031年 9.7667億美元
複合年成長率：2026-2031年 5.91%
成長最快的細分市場 幹細胞療法
最大的市場 北美洲

據「我是漸凍人症」（I AM ALS）組織稱，2024年，該組織的聯合倡導工作成功爭取到2.58億美元的聯邦資金，用於支持漸凍人症的研究和擴大治療範圍的項目。儘管有如此強大的資金支持，市場仍面臨許多挑戰，因為新治療方法往往價格高昂，導致報銷門檻高，患者難以獲得治療。這種經濟障礙，加上後期臨床試驗候選藥物的高退出率，為新參與企業創造了複雜的商業環境。

市場促進因素

來自病患權益倡導團體和非營利基金的大力支持是市場發展的關鍵催化劑，能夠顯著降低早期研發風險，並促進更穩健的研發生態系統的形成。這些組織透過投入大量資金用於探索性生物學和生物標記開發，填補了神經退化性疾病候選藥物經常面臨的資金缺口。正如Target ALS在其2024年年度報告中所述，該組織成功完成了一項2.5億美元的資金籌措宣傳活動，旨在推動創新科學並加速藥物研發的里程碑。這筆未經稀釋的資金注入使生物製藥公司能夠追求高風險、高回報的目標（否則這些目標可能會被忽視），並確保源源不斷的潛在療法進入臨床研發管線。

隨著新製劑和基因藥物成功滲透市場，疾病修正治療療法和症狀管理療法的日益普及，同時也拓寬了商業性前景。治療方法的增加，患者對現有治療方法的持續接受，支撐了產業收入，並凸顯了ALS治療的經濟可行性。例如，三菱田邊製藥於2024年11月宣布，該公司2024會計年度上半年銷售額達2,326億日元，較去年同期成長6.0%。這一成長動能主要歸功於其ALS治療藥物Radica ORS在北美市場的強勁表現。此外，渤健公司於2024年10月報告稱，其罕見疾病業務板塊（包括ALS治療藥物Calsodi）第三季度銷售額達4.95億美元，凸顯了針對神經系統疾病的治療方法的巨大市場價值。

市場挑戰

新治療方法的高昂成本和嚴格的報銷標準對肌萎縮側索硬化症 (ALS) 治療藥物的全球市場商業性擴張構成了重大障礙。儘管臨床開發平臺活躍，但新興藥物的市場潛力往往受限於資金取得。當保險公司和醫療保健機構因藥品價格高而實施限制性報銷政策時，患者的用藥途徑就會受到限制，製藥公司的收入規模也會縮水。這種資金摩擦不僅限制了已通過核准產品的即時市場滲透，也意味著未來相關人員的投資回報波動，並可能減緩產業永續成長所需的長期資本流入。

近期數據顯示，患者群體面臨巨大的經濟壓力，凸顯了這個經濟困境。美國肌萎縮側索硬化症協會引用的一項2025年研究估計，確診肌萎縮側索硬化症後，聯邦醫療保險受益人在一年內將花費超過47,000美元，是普通受益人平均支出的三倍多。如此高昂的支出迫使支付方實施嚴格的報銷標準，延長藥物市場滲透時間，並使新藥進入市場的商業性環境更加複雜。

市場趨勢

反義寡核苷酸（ASO）療法的興起代表著市場格局的重大轉變，它將治療模式從一般的症狀治療轉向針對特定基因突變（例如FUS和SOD1）的精準醫療。這一趨勢的特點是許可活動日益活躍，以及旨在拓展抑制毒性蛋白產生的基因療法產品線的高價值商業合作。例如，2024年11月，大塚製藥株式會社宣布已從​​Ionis公司獲得urefnersen的全球獨家生產和銷售權，urefnersen是一種正在研發用於治療FUS相關ALS的ASO。該協議包括1000萬美元的首付款。這項策略承諾凸顯了業界對基因靜默機製作為未來治療性介入關鍵手段的日益認可。

同時，針對神經發炎和氧化壓力通路的研究正得到策略性加強，旨在解決驅動疾病進展（超出運動神經元保護範圍）的系統性免疫失調問題。生物製藥公司正日益重視免疫調節候選藥物，例如調節性T細胞（Treg）增強療法，以減輕與神經退化相關的發炎級聯反應。在2024年10月的新聞稿中，Coya Therapeutics成功完成了約1000萬美元的私募融資，用於資助其旗艦生物候選藥物COYA 302的臨床和臨床前開發，該藥物靶向這些特異性的抗炎通路。持續湧入以免疫系統為中心的研發管線的資金，凸顯了該產業正轉向採用多機制方法來阻止功能衰退。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球肌萎縮側索硬化症（ALS）治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療類型分類（藥物治療[Riluzole、Edaravone奉等]、幹細胞治療等）
    • 類型（散發性 ALS、遺傳性ALS）
    • 分銷管道（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肌萎縮側索硬化症（ALS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肌萎縮側索硬化症（ALS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肌萎縮側索硬化症（ALS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肌萎縮側索硬化症（ALS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美肌萎縮側索硬化症（ALS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球肌萎縮側索硬化症（ALS）治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Biogen
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • Roche
  • Amylyx Pharmaceuticals
  • Ionis Pharmaceuticals
  • Wave Life Sciences
  • Orphazyme
  • Cleveland Clinic Spinouts
  • Lundbeck

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 26769

The Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market is projected to expand from USD 692.03 Million in 2025 to USD 976.67 Million by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 5.91%. This market includes a variety of pharmaceutical interventions and disease-modifying agents aiming to manage symptoms, slow neurodegeneration, and extend survival for patients with this progressive motor neuron disease. Key drivers of this growth include the rising global incidence of ALS and an aging population, both of which increase the need for effective neurological care. Additionally, significant investment in genetic research and the discovery of novel biomarkers are advancing the clinical development pipeline, establishing a strong foundation for long-term industry expansion beyond temporary market fluctuations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 692.03 Million
Market Size 2031USD 976.67 Million
CAGR 2026-20315.91%
Fastest Growing SegmentStem Cell Therapy
Largest MarketNorth America

According to the I AM ALS organization, collaborative advocacy efforts in 2024 successfully secured $258 million in federal funding to bolster ALS research and expanded access programs. Despite this strong financial support, the market faces considerable challenges due to the high costs of novel therapies, which often encounter strict reimbursement barriers that limit patient accessibility. This economic hurdle, coupled with high attrition rates for drug candidates in late-stage clinical trials, continues to complicate the commercial environment for new market entrants.

Market Driver

Robust support from patient advocacy groups and non-profit funding acts as a vital catalyst for the market, significantly de-risking early-stage research and cultivating a stronger development ecosystem. By directing major capital into discovery biology and biomarker development, these organizations bridge the financial gaps frequently encountered by neurodegenerative therapeutic candidates. As noted in their 2024 Annual Report, Target ALS successfully completed a $250 million capital campaign specifically aimed at fueling innovative science and accelerating drug discovery milestones. This injection of non-dilutive funding enables biopharmaceutical companies to pursue high-risk, high-reward targets that might otherwise be neglected, ensuring a steady flow of potential treatments entering the clinical pipeline.

The rising adoption of disease-modifying and symptom-management therapies is simultaneously broadening the commercial landscape, fueled by the successful market penetration of new formulations and genetic medicines. As therapeutic availability increases, patient uptake of established treatments continues to support industry revenues, confirming the economic viability of ALS therapeutics. For instance, according to Mitsubishi Tanabe Pharma in November 2024, the company achieved a 6.0% year-on-year revenue increase to 232.6 billion yen for the six months ended September 2024, a growth trajectory attributed to the strong performance of its ALS treatment, Radicava ORS, in North America. Additionally, Biogen reported in October 2024 that its rare disease franchise, which includes the ALS therapy Qalsody, generated $495 million in third-quarter revenue, highlighting the substantial market value of targeted neurological interventions.

Market Challenge

The exorbitant cost of novel therapies and the associated strict reimbursement hurdles create a significant barrier to the commercial expansion of the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market. Although the clinical pipeline is active, the market potential for emerging drugs is often limited by economic inaccessibility. When insurers and healthcare systems enforce restrictive coverage policies due to high drug pricing, patient access is constrained, which directly reduces revenue volume for pharmaceutical developers. This financial friction not only limits the immediate market uptake of approved products but also implies a precarious return on investment for future stakeholders, potentially slowing the long-term capital flow needed for sustained industry growth.

This economic difficulty is highlighted by recent data demonstrating the severe financial pressure on the patient population. According to a 2025 study cited by the ALS Association, medical expenses for Medicare beneficiaries in the first year following an ALS diagnosis exceeded $47,000, a figure more than three times higher than that of the average beneficiary. Such high expenditure levels force payers to implement rigorous reimbursement criteria, thereby extending the timeline for market penetration and complicating the commercial landscape for new therapeutic entrants.

Market Trends

The rise of Antisense Oligonucleotide (ASO) therapies marks a critical shift in the market, moving the treatment paradigm from general symptomatic management to precision medicine targeting specific genetic mutations such as FUS and SOD1. This trend is defined by increased licensing activity and high-value commercial partnerships aimed at expanding the pipeline of genetic medicines capable of silencing toxic protein production. For example, Otsuka Pharmaceutical Co., Ltd. announced in November 2024 that it secured exclusive global rights from Ionis to manufacture and market the investigational ASO ulefnersen for FUS-associated ALS, a deal structured with an upfront payment of $10 million. This strategic commitment confirms the growing industrial valuation of gene-silencing mechanisms as a primary modality for future therapeutic interventions.

Simultaneously, there is a strategic intensification of research focusing on neuroinflammation and oxidative stress pathways, looking beyond motor neuron protection to address the systemic immune dysregulation that drives disease progression. Biopharmaceutical developers are increasingly prioritizing immunomodulatory candidates, such as Regulatory T cell (Treg) enhancing therapies, to mitigate the inflammatory cascade associated with neuronal degeneration. According to a press release from Coya Therapeutics in October 2024, the biotechnology firm successfully closed a private placement of approximately $10 million specifically to fund the clinical and preclinical advancement of its lead biologic candidate, COYA 302, which targets these specific anti-inflammatory pathways. This continued capital inflow into immune-centric pipelines highlights the sector's pivot toward multi-mechanistic approaches intended to halt functional decline.

Key Market Players

  • Biogen
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • Roche
  • Amylyx Pharmaceuticals
  • Ionis Pharmaceuticals
  • Wave Life Sciences
  • Orphazyme
  • Cleveland Clinic Spinouts
  • Lundbeck

Report Scope

In this report, the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market, By Treatment

  • Medication
  • Stem Cell Therapy
  • Others

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market, By Type

  • Sporadic ALS
  • Familial ALS

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market.

Available Customizations:

Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Medication [Riluzole, Edaravone, Others], Stem Cell Therapy, Others)
    • 5.2.2. By Type (Sporadic ALS, Familial ALS)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Distribution Channel

7. Europe Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Distribution Channel

10. South America Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Biogen
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Mitsubishi Tanabe Pharma
  • 15.3. Sanofi
  • 15.4. Roche
  • 15.5. Amylyx Pharmaceuticals
  • 15.6. Ionis Pharmaceuticals
  • 15.7. Wave Life Sciences
  • 15.8. Orphazyme
  • 15.9. Cleveland Clinic Spinouts
  • 15.10. Lundbeck

16. Strategic Recommendations

17. About Us & Disclaimer